Bacteriophage-based probiotic preparation for managing Shigella infections

Award Information
Agency:
Department of Defense
Branch
Army
Amount:
$749,969.00
Award Year:
2011
Program:
STTR
Phase:
Phase II
Contract:
W911NF-11-C-0074
Award Id:
n/a
Agency Tracking Number:
A2-4117
Solicitation Year:
2009
Solicitation Topic Code:
A09A-T012
Solicitation Number:
2009.A
Small Business Information
Intralytix, Inc. (Currently INTRALYTIX INC)
The Columbus Center, 701 E. Pratt Street, Baltimore, MD, 21202-
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
005318758
Principal Investigator:
Alexander Sulakvelidze
Chief Scientist
(410) 625-2533
asulakvelidze@intralytix.com
Business Contact:
John Woloszyn
President and CEO
(410) 625-3813
jwoloszyn@intralytix.com
Research Institution:
University of Florida
Brian Prindle
Division of Sponsored Programs
219 Grinter Hall
Gainesville, FL, 23611-
(352) 392-3516
Nonprofit college or university
Abstract
During the studies supported by our Phase I STTR grant from the US Army, we began developing and testing a novel concept for a probiotic preparation based on naturally occurring bacteriophages as a way to condition the GI tract"s microflora gently and favorably. The preparation (tentatively designated"ShigActive") is a bacteriophage cocktail that specifically targets Shigella spp. (significant diarrhea-causing pathogens that sicken ca. 165 million people/year, ca. 1.1 million of whom die). We have succesfully isolated and rigorously characterized a large number of phages lytic for Shigella, and we have developed a murine model in which the in vivo efficacy of our phage preparation can be evaluated. During this Phase II project, we propose to perform studies required to obtain regulatory approval of ShigActive. During these studies, we will also perform metagenomic analyses of the gut microbiota (using DGGE and state-of-the-art 454-pyrosequencing of 16S rRNA genes) of mice before and after their treatment with ShigActive, in order to (i) obtain additional safety data for the FDA, and (ii) compare rigorously the effect of ShigActive and ampicillin (an antibiotic commonly used to treat shigellosis) on the intestinal microflora of mice. The proposed project"s primary goal is to submit a New Dietary Ingredient (NDI) Notification to the FDA, whose approval will enable us to commence commercial sales of ShigActive.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government